Purple Biotech Ltd (PPBT): Price and Financial Metrics


Purple Biotech Ltd (PPBT): $2.87

-0.19 (-6.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PPBT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PPBT Stock Price Chart Interactive Chart >

Price chart for PPBT

PPBT Price/Volume Stats

Current price $2.87 52-week high $6.75
Prev. close $3.06 52-week low $2.44
Day low $2.73 Volume 124,500
Day high $2.98 Avg. volume 100,463
50-day MA $3.30 Dividend yield N/A
200-day MA $3.82 Market Cap 74.45M

Purple Biotech Ltd (PPBT) Company Bio


Purple Biotech Ltd operates as a pharmaceutical company. The Company discovers and develops medicines, drugs, and other pharmaceutical products for the treatment of osteoarthritis pain and hypertension. Purple Biotech serves customers globally.


PPBT Latest News Stream


Event/Time News Detail
Loading, please wait...

PPBT Latest Social Stream


Loading social stream, please wait...

View Full PPBT Social Stream

Latest PPBT News From Around the Web

Below are the latest news stories about Purple Biotech Ltd that investors may wish to consider to help them evaluate PPBT as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | March 24, 2022

Could The Solid State plc (LON:SOLI) Ownership Structure Tell Us Something Useful?

The big shareholder groups in Solid State plc ( LON:SOLI ) have power over the company. Insiders often own a large...

Yahoo | February 24, 2022

Purple Biotech Reports Second Half and Full-Year 2021 Financial Results

REHOVOT, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced financial results for the year and the six months ended December 31, 2021. “We achieved significant progress in the advancement of our promising oncology pipeline during this year with notable data releases in both

Yahoo | February 9, 2022

Purple Biotech Issues Letter to Shareholders

REHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, is pleased to issue the following letter from its Chief Executive Officer, Isaac Israel, to its shareholders. View as PDF Dear shareholders, I look back at 2021 proudly as a foundation-setting year for Purple Biotech, one with clin

Yahoo | February 4, 2022

Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors

REHOVOT, Israel, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Ori Hershkovitz, a long-time life sciences industry investor, to its Board of Directors. “We are thrilled to welcome Ori to the Purple Biotech Board of Directors,” said Dr. Eric Rowinsky, Chairman

Yahoo | January 6, 2022

Read More 'PPBT' Stories Here

PPBT Price Returns

1-mo -2.71%
3-mo -1.71%
6-mo -27.71%
1-year -47.44%
3-year N/A
5-year N/A
YTD -26.22%
2021 2.10%
2020 -51.13%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5133 seconds.